Table of Contents Chapter 1 Overview of Peptide Antibiotics 1.1 Definition of Peptide Antibiotics in This Report 1.2 Commercial Types of Peptide Antibiotics 1.2.1 Ribosomal Synthesized Peptide Antibiotics 1.2.2 Non-Ribosomally Synthesized Peptide Antibiotics 1.3 Downstream Application of Peptide Antibiotics 1.3.1 Pharma & Healthcare 1.3.2 Food Industry 1.3.3 Commodities 1.3.4 Other 1.4 Development History of Peptide Antibiotics 1.5 Market Status and Trend of Peptide Antibiotics 2013-2023 1.5.1 United States Peptide Antibiotics Market Status and Trend 2013-2023 1.5.2 Regional Peptide Antibiotics Market Status and Trend 2013-2023 Chapter 2 United States Market Status and Forecast by Regions 2.1 Market Status of Peptide Antibiotics in United States 2013-2017 2.2 Consumption Market of Peptide Antibiotics in United States by Regions 2.2.1 Consumption Volume of Peptide Antibiotics in United States by Regions 2.2.2 Revenue of Peptide Antibiotics in United States by Regions 2.3 Market Analysis of Peptide Antibiotics in United States by Regions 2.3.1 Market Analysis of Peptide Antibiotics in New England 2013-2017 2.3.2 Market Analysis of Peptide Antibiotics in The Middle Atlantic 2013-2017 2.3.3 Market Analysis of Peptide Antibiotics in The Midwest 2013-2017 2.3.4 Market Analysis of Peptide Antibiotics in The West 2013-2017 2.3.5 Market Analysis of Peptide Antibiotics in The South 2013-2017 2.3.6 Market Analysis of Peptide Antibiotics in Southwest 2013-2017 2.4 Market Development Forecast of Peptide Antibiotics in United States 2018-2023 2.4.1 Market Development Forecast of Peptide Antibiotics in United States 2018-2023 2.4.2 Market Development Forecast of Peptide Antibiotics by Regions 2018-2023 Chapter 3 United States Market Status and Forecast by Types 3.1 Whole United States Market Status by Types 3.1.1 Consumption Volume of Peptide Antibiotics in United States by Types 3.1.2 Revenue of Peptide Antibiotics in United States by Types 3.2 United States Market Status by Types in Major Countries 3.2.1 Market Status by Types in New England 3.2.2 Market Status by Types in The Middle Atlantic 3.2.3 Market Status by Types in The Midwest 3.2.4 Market Status by Types in The West 3.2.5 Market Status by Types in The South 3.2.6 Market Status by Types in Southwest 3.3 Market Forecast of Peptide Antibiotics in United States by Types Chapter 4 United States Market Status and Forecast by Downstream Industry 4.1 Demand Volume of Peptide Antibiotics in United States by Downstream Industry 4.2 Demand Volume of Peptide Antibiotics by Downstream Industry in Major Countries 4.2.1 Demand Volume of Peptide Antibiotics by Downstream Industry in New England 4.2.2 Demand Volume of Peptide Antibiotics by Downstream Industry in The Middle Atlantic 4.2.3 Demand Volume of Peptide Antibiotics by Downstream Industry in The Midwest 4.2.4 Demand Volume of Peptide Antibiotics by Downstream Industry in The West 4.2.5 Demand Volume of Peptide Antibiotics by Downstream Industry in The South 4.2.6 Demand Volume of Peptide Antibiotics by Downstream Industry in Southwest 4.3 Market Forecast of Peptide Antibiotics in United States by Downstream Industry Chapter 5 Market Driving Factor Analysis of Peptide Antibiotics 5.1 United States Economy Situation and Trend Overview 5.2 Peptide Antibiotics Downstream Industry Situation and Trend Overview Chapter 6 Peptide Antibiotics Market Competition Status by Major Players in United States 6.1 Sales Volume of Peptide Antibiotics in United States by Major Players 6.2 Revenue of Peptide Antibiotics in United States by Major Players 6.3 Basic Information of Peptide Antibiotics by Major Players 6.3.1 Headquarters Location and Established Time of Peptide Antibiotics Major Players 6.3.2 Employees and Revenue Level of Peptide Antibiotics Major Players 6.4 Market Competition News and Trend 6.4.1 Merger, Consolidation or Acquisition News 6.4.2 Investment or Disinvestment News 6.4.3 New Product Development and Launch Chapter 7 Peptide Antibiotics Major Manufacturers Introduction and Market Data 7.1 Pfizer 7.1.1 Company profile 7.1.2 Representative Peptide Antibiotics Product 7.1.3 Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Pfizer 7.2 Novartis 7.2.1 Company profile 7.2.2 Representative Peptide Antibiotics Product 7.2.3 Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Novartis 7.3 GlaxoSmithKline 7.3.1 Company profile 7.3.2 Representative Peptide Antibiotics Product 7.3.3 Peptide Antibiotics Sales, Revenue, Price and Gross Margin of GlaxoSmithKline 7.4 Eli Lilly 7.4.1 Company profile 7.4.2 Representative Peptide Antibiotics Product 7.4.3 Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Eli Lilly 7.5 Theravance 7.5.1 Company profile 7.5.2 Representative Peptide Antibiotics Product 7.5.3 Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Theravance 7.6 Vicuron Pharmaceuticals 7.6.1 Company profile 7.6.2 Representative Peptide Antibiotics Product 7.6.3 Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Vicuron Pharmaceuticals 7.7 Savara Pharmaceuticals 7.7.1 Company profile 7.7.2 Representative Peptide Antibiotics Product 7.7.3 Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Savara Pharmaceuticals 7.8 AMP Therapeutics 7.8.1 Company profile 7.8.2 Representative Peptide Antibiotics Product 7.8.3 Peptide Antibiotics Sales, Revenue, Price and Gross Margin of AMP Therapeutics 7.9 Hospira 7.9.1 Company profile 7.9.2 Representative Peptide Antibiotics Product 7.9.3 Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Hospira 7.10 Kasten 7.10.1 Company profile 7.10.2 Representative Peptide Antibiotics Product 7.10.3 Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Kasten 7.11 Madam Therapeutics 7.11.1 Company profile 7.11.2 Representative Peptide Antibiotics Product 7.11.3 Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Madam Therapeutics 7.12 Phosphagenics 7.12.1 Company profile 7.12.2 Representative Peptide Antibiotics Product 7.12.3 Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Phosphagenics 7.13 Pacgen Life Science Corporation 7.13.1 Company profile 7.13.2 Representative Peptide Antibiotics Product 7.13.3 Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Pacgen Life Science Corporation Chapter 8 Upstream and Downstream Market Analysis of Peptide Antibiotics 8.1 Industry Chain of Peptide Antibiotics 8.2 Upstream Market and Representative Companies Analysis 8.3 Downstream Market and Representative Companies Analysis Chapter 9 Cost and Gross Margin Analysis of Peptide Antibiotics 9.1 Cost Structure Analysis of Peptide Antibiotics 9.2 Raw Materials Cost Analysis of Peptide Antibiotics 9.3 Labor Cost Analysis of Peptide Antibiotics 9.4 Manufacturing Expenses Analysis of Peptide Antibiotics Chapter 10 Marketing Status Analysis of Peptide Antibiotics 10.1 Marketing Channel 10.1.1 Direct Marketing 10.1.2 Indirect Marketing 10.1.3 Marketing Channel Development Trend 10.2 Market Positioning 10.2.1 Pricing Strategy 10.2.2 Brand Strategy 10.2.3 Target Client 10.3 Distributors/Traders List Chapter 11 Report Conclusion Chapter 12 Research Methodology and Reference 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Reference

List of Tables Table Advantage and Disadvantage of Ribosomal Synthesized Peptide Antibiotics Table Advantage and Disadvantage of Non-Ribosomally Synthesized Peptide Antibiotics Table Consumption Volume of Peptide Antibiotics in United States by Regions 2013-2017 Table Revenue of Peptide Antibiotics in United States by Regions 2013-2017 Table Consumption Volume of Peptide Antibiotics in United States by Regions 2018-2023 Table Revenue of Peptide Antibiotics in United States by Regions 2018-2023 Table Consumption Volume of Peptide Antibiotics in United States by Types 2013-2017 Table Revenue of Peptide Antibiotics in United States by Types 2013-2017 Table Consumption Volume of Peptide Antibiotics by Types in New England 2013-2017 Table Consumption Volume of Peptide Antibiotics by Types in The Middle Atlantic 2013-2017 Table Consumption Volume of Peptide Antibiotics by Types in The Midwest 2013-2017 Table Consumption Volume of Peptide Antibiotics by Types in The West 2013-2017 Table Consumption Volume of Peptide Antibiotics by Types in The South 2013-2017 Table Consumption Volume of Peptide Antibiotics by Types in Southwest 2013-2017 Table Consumption Volume Forecast of Peptide Antibiotics in United States by Types 2018-2023 Table Revenue Forecast of Peptide Antibiotics in United States by Types 2018-2023 Table Demand Volume of Peptide Antibiotics in United States by Downstream Industry 2013-2017 Table Demand Volume of Peptide Antibiotics by Downstream Industry in New England 2013-2017 Table Demand Volume of Peptide Antibiotics by Downstream Industry in The Middle Atlantic 2013-2017 Table Demand Volume of Peptide Antibiotics by Downstream Industry in The Midwest 2013-2017 Table Demand Volume of Peptide Antibiotics by Downstream Industry in The West 2013-2017 Table Demand Volume of Peptide Antibiotics by Downstream Industry in The South 2013-2017 Table Demand Volume of Peptide Antibiotics by Downstream Industry in Southwest 2013-2017 Table Demand Volume Forecast of Peptide Antibiotics in United States by Downstream Industry 2018-2023 Table Sales Volume of Peptide Antibiotics in United States by Major Players 2013-2017 Table Revenue of Peptide Antibiotics in United States by Major Players 2013-2017 Table Headquarters Location and Established Time of Peptide Antibiotics Major Players Table Employees and Revenue Level of Peptide Antibiotics Major Players Table Representative Peptide Antibiotics Product One of Pfizer Table Representative Peptide Antibiotics Product Two of Pfizer Table Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Pfizer 2013-2017 Table Representative Peptide Antibiotics Product One of Novartis Table Representative Peptide Antibiotics Product Two of Novartis Table Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Novartis 2013-2017 Table Representative Peptide Antibiotics Product One of GlaxoSmithKline Table Representative Peptide Antibiotics Product Two of GlaxoSmithKline Table Peptide Antibiotics Sales, Revenue, Price and Gross Margin of GlaxoSmithKline 2013-2017 Table Representative Peptide Antibiotics Product One of Eli Lilly Table Representative Peptide Antibiotics Product Two of Eli Lilly Table Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Eli Lilly 2013-2017 Table Representative Peptide Antibiotics Product One of Theravance Table Representative Peptide Antibiotics Product Two of Theravance Table Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Theravance 2013-2017 Table Representative Peptide Antibiotics Product One of Vicuron Pharmaceuticals Table Representative Peptide Antibiotics Product Two of Vicuron Pharmaceuticals Table Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Vicuron Pharmaceuticals 2013-2017 Table Representative Peptide Antibiotics Product One of Savara Pharmaceuticals Table Representative Peptide Antibiotics Product Two of Savara Pharmaceuticals Table Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Savara Pharmaceuticals 2013-2017 Table Representative Peptide Antibiotics Product One of AMP Therapeutics Table Representative Peptide Antibiotics Product Two of AMP Therapeutics Table Peptide Antibiotics Sales, Revenue, Price and Gross Margin of AMP Therapeutics 2013-2017 Table Representative Peptide Antibiotics Product One of Hospira Table Representative Peptide Antibiotics Product Two of Hospira Table Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Hospira 2013-2017 Table Representative Peptide Antibiotics Product One of Kasten Table Representative Peptide Antibiotics Product Two of Kasten Table Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Kasten 2013-2017 Table Representative Peptide Antibiotics Product One of Madam Therapeutics Table Representative Peptide Antibiotics Product Two of Madam Therapeutics Table Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Madam Therapeutics 2013-2017 Table Representative Peptide Antibiotics Product One of Phosphagenics Table Representative Peptide Antibiotics Product Two of Phosphagenics Table Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Phosphagenics 2013-2017 Table Representative Peptide Antibiotics Product One of Pacgen Life Science Corporation Table Representative Peptide Antibiotics Product Two of Pacgen Life Science Corporation Table Peptide Antibiotics Sales, Revenue, Price and Gross Margin of Pacgen Life Science Corporation 2013-2017